4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

Core Insights - 4D Molecular Therapeutics is accelerating the 4D-150 4FRONT Phase 3 program for wet age-related macular degeneration (wet AMD) and has streamlined operations to manage increased expenses, ensuring cash runway into 2028 [1][6] - The company anticipates topline data for the 4FRONT-1 trial in the first half of 2027, an acceleration from the previous guidance of the second half of 2027 [3][6] - A workforce reduction of approximately 25% is being implemented to achieve annual cash compensation savings of about $15 million, supporting the accelerated clinical trial timelines [6] Company Overview - 4D-150 is designed as a backbone therapy for retinal vascular diseases, providing multi-year sustained delivery of anti-VEGF through a single intravitreal injection [5][9] - The company has a strong cash position with $458 million in cash, cash equivalents, and marketable securities as of March 31, 2025, sufficient to support ongoing clinical trials and preparations [6] - The company is transitioning towards becoming a commercial entity, focusing on delivering transformative genetic medicines to patients [4][9] Clinical Development - Initial enrollment and site activation for the 4FRONT-1 trial have exceeded projections, indicating strong engagement from investigators and patients [6] - The 4FRONT-2 trial has been initiated ahead of schedule, with topline data expected in the second half of 2027 [5][6] - Wet AMD is a prevalent disease, with over 4 million individuals expected to be affected in major markets within the next five years [8]